Morse GD, Reichman RC, Fischl MA, et al. (January 2000). "Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams". Antiviral Res. 45 (1): 47–58. doi:10.1016/S0166-3542(99)00073-X. PMID10774589.
Romero, D. L.; Morge, R. A.; Biles, C.; Berrios-Pena, N.; May, P. D.; Palmer, J. R.; Johnson, P. D.; Smith, H. W.; Busso, M.; et al. (1994). "Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors". Journal of Medicinal Chemistry. 37 (7): 999–1014. doi:10.1021/jm00033a018. PMID7512142.
espacenet.com
worldwide.espacenet.com
WO 9109849, Romero, Donna Lee; Mitchell, Mark Allen & Thomas, Richard Charles et al., "Diaromatic substituted anti-AIDS compounds", published 1991-07-11, assigned to Upjohn
nih.gov
pubmed.ncbi.nlm.nih.gov
Morse GD, Reichman RC, Fischl MA, et al. (January 2000). "Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams". Antiviral Res. 45 (1): 47–58. doi:10.1016/S0166-3542(99)00073-X. PMID10774589.
Romero, D. L.; Morge, R. A.; Biles, C.; Berrios-Pena, N.; May, P. D.; Palmer, J. R.; Johnson, P. D.; Smith, H. W.; Busso, M.; et al. (1994). "Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors". Journal of Medicinal Chemistry. 37 (7): 999–1014. doi:10.1021/jm00033a018. PMID7512142.